Mizuho Boosts CVS Health (NYSE:CVS) Price Target to $76.00

CVS Health (NYSE:CVS - Get Free Report) had its price target lifted by research analysts at Mizuho from $70.00 to $76.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an "outperform" rating on the pharmacy operator's stock. Mizuho's price target would suggest a potential upside of 9.67% from the stock's current price.

CVS has been the topic of several other reports. Barclays upped their target price on shares of CVS Health from $71.00 to $73.00 and gave the stock an "overweight" rating in a research report on Thursday, February 13th. Piper Sandler boosted their target price on CVS Health from $72.00 to $74.00 and gave the stock an "overweight" rating in a research report on Friday, March 21st. StockNews.com raised CVS Health from a "sell" rating to a "hold" rating in a research note on Thursday, February 13th. Evercore ISI increased their price objective on shares of CVS Health from $60.00 to $65.00 and gave the company an "outperform" rating in a research note on Monday, January 27th. Finally, Wolfe Research upped their price target on shares of CVS Health from 67.00 to 70.00 and gave the company an "overweight" rating in a report on Tuesday, February 11th. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, CVS Health presently has an average rating of "Moderate Buy" and a consensus target price of $71.28.

CVS Health Stock Performance

NYSE:CVS traded down $0.21 during mid-day trading on Wednesday, reaching $69.30. The stock had a trading volume of 3,098,452 shares, compared to its average volume of 11,732,582. The firm has a market capitalization of $87.37 billion, a price-to-earnings ratio of 18.93, a PEG ratio of 0.98 and a beta of 0.57. The business has a 50 day simple moving average of $65.10 and a 200 day simple moving average of $58.51. CVS Health has a twelve month low of $43.56 and a twelve month high of $71.66. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, topping analysts' consensus estimates of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. On average, analysts expect that CVS Health will post 5.89 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, SVP James David Clark sold 7,513 shares of the firm's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total transaction of $498,487.55. Following the sale, the senior vice president now directly owns 8,394 shares in the company, valued at approximately $556,941.90. This trade represents a 47.23 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Michael F. Mahoney purchased 30,000 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was bought at an average price of $66.70 per share, with a total value of $2,001,000.00. Following the acquisition, the director now owns 39,356 shares in the company, valued at $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.24% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CVS. Ridgewood Investments LLC boosted its position in CVS Health by 255.7% in the 4th quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator's stock valued at $28,000 after buying an additional 450 shares during the last quarter. Stonebridge Financial Group LLC purchased a new stake in CVS Health during the 4th quarter worth approximately $28,000. Hopwood Financial Services Inc. acquired a new position in shares of CVS Health in the 4th quarter valued at approximately $29,000. McIlrath & Eck LLC grew its position in shares of CVS Health by 32.6% during the fourth quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator's stock worth $32,000 after buying an additional 174 shares in the last quarter. Finally, Financial Perspectives Inc increased its stake in shares of CVS Health by 137.5% in the fourth quarter. Financial Perspectives Inc now owns 805 shares of the pharmacy operator's stock worth $36,000 after buying an additional 466 shares during the last quarter. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.